Prothena's PRX002, a preclinical treatment targeting Parkinson's disease, is at the heart of a deal with Swiss pharma giant Roche, worth up to $600 million plus 30% of U.S. profits to the Irish biotech.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.
Echo Therapeutics has found a lifeline, a development partner in Asia that will help the Philadelphia device company accelerate efforts to bring its cutting-edge glucose monitor into the Chinese market.
Alliqua Biomedical is a relatively small maker of hydrogel wound care and drug delivery systems looking to delve into the hot regenerative medicine space, and a recent investment from Celgene has given the company a chance at a higher profile in the arena.
CareFusion has its eye on an Israeli infusion pump maker and will invest $100 million in the company's operations, the San Diego med tech company's second big deal in the last month.
Biogen Idec is sticking close to its research home in Cambridge, MA, in its latest neurodegenerative drug development pact. The big biotech is teaming up with the neighboring Proteostasis Therapeutics on a potential new approach for attacking toxic proteins implicated in the development of Alzheimer's and Parkinson's diseases.
Boston Children's Hospital spinout Claritas Genomics, a genetic diagnostic testing company, attracted an investment from IT specialist Cerner, and the two will collaborate to develop a computing infrastructure designed to smooth the diagnostic process from start to finish.
Switzerland's Biocartis will link up with Belgium's VIB research institute to develop a diagnostic test useful for colorectal and other cancers, the company said.
Well-traveled biotech luminary Michael Foley has agreed to head up a new translational research effort that unites minds at Weill Cornell Medical College, the Rockefeller University and Memorial Sloan-Kettering Cancer Center with the mission of turning exciting lab work into promising drug candidates.
GlaxoSmithKline is launching what it calls the Oncology Clinical and Translational Consortium, a collaborative scientific research network intended to advance drug discovery that will include 6 cancer centers around the world.